Clinical Trials:
– PURPOSE 1: The trial involved over 5,300 cisgender women and adolescent girls in South Africa and Uganda.
– PURPOSE 2: The trial assessed lenacapavir’s efficacy in cisgender men who have sex with men, transgender men, transgender women, and gender non-binary individuals.
Future Plans:
